The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumothorax
Does not usually occur in isolation, but rather as a complication of bleomycin-induced pneumonitis/fibrosis, or as a manifestation of barotrauma in those patients under mechanical ventilation for bleomycin-induced respiratory failure
Publications
[Fatal bleomycin induced pneumomediastinum and bilateral pneumothorax].
Revue de pneumologie clinique. 2017;73(3):153-156
Tashiro M, Izumikawa K, Yoshioka D, Nakamura S, Kurihara S, Sakamoto N, Seki M, Kakeya H, Yamamoto Y, Yanagihara K, Mukae H, Hayashi T, Fukushima K, Tashiro T, Kohno S
Lung fibrosis 10 years after cessation of bleomycin therapy.
The Tohoku journal of experimental medicine. 2008;216(1):77-80
Extensive pneumothorax, pneumomediastinum and surgical emphysema as a complication of bleomycin therapy.
Pediatric radiology. 2005;35(12):1227-9
Hudson MM, Greenwald C, Thompson E, Wilimas J, Marina N, Fairclough D, Kauffman W, Bozeman P, Mackert PW, Abromowitch M
Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993;11(1):100-8
Fatal pneumothorax following bleomycin and other cytotoxic drugs.
Cancer treatment reports. 1985;69(3):344-5